{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-22-000016","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.493260+00:00","generated_at":"2026-06-25T21:56:40.785050+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tarsus Q1 net loss $20.2M; TP-03 hits all endpoints in Saturn-2 Phase 3","bullets":["Q1 net loss $20.2M vs net income $10.4M YoY; license revenue $0.5M vs $33.4M.","TP-03 met primary and all secondary endpoints in Saturn-2 Phase 3 for Demodex blepharitis; NDA submission H2 2022.","Cash $175.3M at March 31; completed $71M net equity raise in May; cash runway into at least 2026.","TP-05 Phase 1b Callisto data expected H2 2022; TP-04 Phase 2 for rosacea planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-22-000016","json":"https://secwatch.observer/filing/0001819790-22-000016.json","markdown":"https://secwatch.observer/filing/0001819790-22-000016.md","text":"https://secwatch.observer/filing/0001819790-22-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000016/0001819790-22-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000016/tars-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:56:40.785050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}